Diagnostic Center | April 15, 2025
Dr. Lal PathLabs becomes South Asia's first to launch advanced test for amyloidosis
More than 40 types of Amyloid proteins are discovered till date
More than 40 types of Amyloid proteins are discovered till date
Final decision from the European Commission is anticipated within the coming months
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR
US FDA approval based on NEURO-TTRansform Phase III results
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition
It is a novel oral NLRP3 inflammasome inhibitor
Subscribe To Our Newsletter & Stay Updated
